Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that Frontiers in
Adobe Inc (NASDAQ: ADBE) shares have fallen significantly since the start of the year and the decline is only getting worse as the stock continues to trade lower Wednesday following weak guidance.